Skip to main content
. Author manuscript; available in PMC: 2017 Mar 15.
Published in final edited form as: J Immunol. 2016 Feb 3;196(6):2742–2752. doi: 10.4049/jimmunol.1502331

Fig. 6. AT-RvD1 promotes M2 macrophages to mediate NTHi clearance.

Fig. 6

Mice were treated with AT-RvD1 (veh- black bars, 20ng/mouse- dark grey bars, or 100ng/mouse- light grey bars, OA) and/or NTHi (1 × 106 CFUs, OA) for 8hrs. Macrophages and neutrophils were obtained from bronchoalveolar lavage (A-D) and collagenase digestion (E-H). Macrophage phenotype was assessed by flow cytometry (A, E). Uptake of NTHi by CD80+ macrophages, CD206+ macrophages, and neutrophils was also assessed by flow cytometry in bronchoalveolar lavage (B-D) and collagenase digested lungs (F-H). Statistical significance was determined by two-way ANOVA (overall p<0.0001 NTHi [all panels], p=0.0288 AT-RvD1 [A], p=0.0018 AT-RvD1 [F], p<0.0001 AT-RvD1 [G], p=0.0032 AT-RvD1 [H]) with Bonferroni’s posttest for multiple comparisons (*p<0.05, **p<0.01, ***p<0.001, ****p<0.0001), n=3-6 mice/group.